Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 807

1.

Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis.

Burmester GR, Gordon KB, Rosenbaum JT, Arikan D, Lau WL, Li P, Faccin F, Panaccione R.

Adv Ther. 2020 Jan;37(1):364-380. doi: 10.1007/s12325-019-01145-8. Epub 2019 Nov 20.

PMID:
31748904
2.

Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies.

Cheng Q, Pelz A, Taddeo A, Khodadadi L, Klotsche J, Hoyer BF, Alexander T, Thiel A, Burmester GR, Radbruch A, Hiepe F.

Eur J Immunol. 2019 Nov 12. doi: 10.1002/eji.201948144. [Epub ahead of print]

PMID:
31714996
3.

Pathogenic memory plasma cells in autoimmunity.

Chang HD, Tokoyoda K, Hoyer B, Alexander T, Khodadadi L, Mei H, Dörner T, Hiepe F, Burmester GR, Radbruch A.

Curr Opin Immunol. 2019 Dec;61:86-91. doi: 10.1016/j.coi.2019.09.005. Epub 2019 Oct 30. Review. No abstract available.

4.

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.

Burmester GR, Strand V, Rubbert-Roth A, Amital H, Raskina T, Gómez-Centeno A, Pena-Rossi C, Gervitz L, Thangavelu K, St John G, Boklage S, Genovese MC.

RMD Open. 2019 Oct 18;5(2):e001017. doi: 10.1136/rmdopen-2019-001017. eCollection 2019.

5.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.

Winthrop KL, Weinblatt ME, Bathon J, Burmester GR, Mease PJ, Crofford L, Bykerk V, Dougados M, Rosenbaum JT, Mariette X, Sieper J, Melchers F, Cronstein BN, Breedveld FC, Kalden J, Smolen JS, Furst D.

Ann Rheum Dis. 2020 Jan;79(1):88-93. doi: 10.1136/annrheumdis-2019-216151. Epub 2019 Oct 29. Review.

6.

IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis.

Rose A, von Spee-Mayer C, Kloke L, Wu K, Kühl A, Enghard P, Burmester GR, Riemekasten G, Humrich JY.

Cells. 2019 Oct 11;8(10). pii: E1234. doi: 10.3390/cells8101234.

7.

EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases.

Najm A, Nikiphorou E, Kostine M, Richez C, Pauling JD, Finckh A, Ritschl V, Prior Y, Balážová P, Stones S, Szekanecz Z, Iagnocco A, Ramiro S, Sivera F, Dougados M, Carmona L, Burmester G, Wiek D, Gossec L, Berenbaum F.

RMD Open. 2019 Sep 13;5(2):e001014. doi: 10.1136/rmdopen-2019-001014. eCollection 2019.

8.

Fluoreszenzoptische Bildgebung zum Nachweis einer möglichen Psoriasisarthritis im Vergleich zum muskuloskelettalen Ultraschall.

Erdmann-Keding M, Ohrndorf S, Werner SG, Glimm AM, Burmester GR, Kokolakis G, Zuberbier T, Sterry W, Backhaus M, Philipp S.

J Dtsch Dermatol Ges. 2019 Sep;17(9):913-922. doi: 10.1111/ddg.13931_g. German.

PMID:
31538745
9.

Fluorescence optical imaging for the detection of potential psoriatic arthritis in comparison to musculoskeletal ultrasound.

Erdmann-Keding M, Ohrndorf S, Werner SG, Glimm AM, Burmester GR, Kokolakis G, Zuberbier T, Sterry W, Backhaus M, Philipp S.

J Dtsch Dermatol Ges. 2019 Sep;17(9):913-921. doi: 10.1111/ddg.13931.

PMID:
31538737
10.

Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period.

Glimm AM, Sprenger LI, Haugen IK, Mansmann U, Hermann S, Häupl T, Hoff P, Burmester GR, Backhaus M, Le L, Ohrndorf S.

Arthritis Res Ther. 2019 Sep 18;21(1):209. doi: 10.1186/s13075-019-1989-5.

11.

Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.

Sepriano A, Ramiro S, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP.

J Rheumatol. 2019 Sep 15. pii: jrheum.190303. doi: 10.3899/jrheum.190303. [Epub ahead of print]

PMID:
31523049
12.

The International RA BIODAM Cohort for Validation of Soluble Biomarkers in Rheumatoid Arthritis: Cohort Description.

Maksymowych WP, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Lambert RG, Elkayam O, Ramiro S, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Allaart R, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Sepriano A, Landewé R.

J Rheumatol. 2019 Sep 1. pii: jrheum.190302. doi: 10.3899/jrheum.190302. [Epub ahead of print]

PMID:
31474600
13.

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment.

Genovese MC, van der Heijde D, Lin Y, St John G, Wang S, van Hoogstraten H, Gómez-Reino JJ, Kivitz A, Maldonado-Cocco JA, Seriolo B, Stanislav M, Burmester GR.

RMD Open. 2019 Aug 1;5(2):e000887. doi: 10.1136/rmdopen-2018-000887. eCollection 2019.

14.

Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations.

Kedra J, Radstake T, Pandit A, Baraliakos X, Berenbaum F, Finckh A, Fautrel B, Stamm TA, Gomez-Cabrero D, Pristipino C, Choquet R, Servy H, Stones S, Burmester G, Gossec L.

RMD Open. 2019 Jul 18;5(2):e001004. doi: 10.1136/rmdopen-2019-001004. eCollection 2019.

15.

Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.

Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, Gomez-Reino JJ, Maldonado-Cocco JA, Stanislav M, Kivitz AJ, Burmester GR.

Rheumatology (Oxford). 2019 Jul 15. pii: kez265. doi: 10.1093/rheumatology/kez265. [Epub ahead of print]

PMID:
31312844
16.

EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases.

Gossec L, Kedra J, Servy H, Pandit A, Stones S, Berenbaum F, Finckh A, Baraliakos X, Stamm TA, Gomez-Cabrero D, Pristipino C, Choquet R, Burmester GR, Radstake TRDJ.

Ann Rheum Dis. 2020 Jan;79(1):69-76. doi: 10.1136/annrheumdis-2019-215694. Epub 2019 Jun 22.

PMID:
31229952
17.

[Treat to target: therapeutic aims/prognosis parameters].

Schneider M, Burmester GR.

Z Rheumatol. 2019 Jun;78(5):394-395. doi: 10.1007/s00393-019-0638-3. German. No abstract available.

PMID:
31172315
18.

16p13.11 microdeletion uncovers loss-of-function of a MYH11 missense variant in a patient with megacystis-microcolon-intestinal-hypoperistalsis syndrome.

Kloth K, Renner S, Burmester G, Steinemann D, Pabst B, Lorenz B, Simon R, Kolbe V, Hempel M, Rosenberger G.

Clin Genet. 2019 Jul;96(1):85-90. doi: 10.1111/cge.13557. Epub 2019 May 16.

PMID:
31044419
19.

Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI).

Dörner T, Schulze-Koops H, Burmester GR, Iking-Konert C, Schmalzing M, Engel A, Kästner P, Kellner H, Kurthen R, Krüger K, Rubbert-Roth A, Schwenke H, Peters MA, Tony HP.

Clin Exp Rheumatol. 2019 Nov-Dec;37(6):937-945. Epub 2019 Apr 16.

20.

[Tight control-Demand for short term control of rheumatoid arthritis].

Schneider M, Burmester GR.

Z Rheumatol. 2019 Jun;78(5):404-412. doi: 10.1007/s00393-019-0631-x. Review. German.

PMID:
31001653
21.

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study.

Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Maldonado MA, Huizinga TW.

RMD Open. 2019 Feb 8;5(1):e000840. doi: 10.1136/rmdopen-2018-000840. eCollection 2019.

22.

Association between baseline clinical and imaging findings and the development of digital ulcers in patients with systemic sclerosis.

Friedrich S, Lüders S, Glimm AM, Werner SG, Schmittat G, Burmester GR, Backhaus M, Riemekasten G, Ohrndorf S.

Arthritis Res Ther. 2019 Apr 15;21(1):96. doi: 10.1186/s13075-019-1875-1.

23.

Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected].

Meyer A, Scirè CA, Talarico R, Alexander T, Amoura Z, Avcin T, Barsotti S, Beretta L, Blagojevic J, Burmester G, Cavazzana I, Cherrin P, Damian L, Doria A, Fonseca JE, Furini F, Galetti I, Houssiau F, Krieg T, Maddalena L, Launay D, Campanilho-Marques R, Martin T, Matucci-Cerinic M, Moinzadeh P, Montecucco C, Moraes-Fontes MF, Mouthon L, Neri R, Paolino S, Piette Y, Rednic S, Tamirou F, Tincani A, Toplak N, Bombardieri S, Hachulla E, Mueller-Ladner U, Schneider M, Smith V, Vieira A, Cutolo M, Mosca M, Cavagna L.

RMD Open. 2019 Feb 26;4(Suppl 1):e000784. doi: 10.1136/rmdopen-2018-000784. eCollection 2018. Review. Erratum in: RMD Open. 2019 Apr 15;5(1):e000784corr1.

24.

Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor Inhibitor Therapy in Ankylosing Spondylitis: A German GO-NICE Study Subanalysis.

Braun J, Baraliakos X, Kiltz U, Krüger K, Burmester GR, Wassenberg S, Thomas MH.

J Rheumatol. 2020 Jan;47(1):35-41. doi: 10.3899/jrheum.181040. Epub 2019 Mar 15.

25.

Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study.

Burmester G, Nüsslein H, von Hinüber U, Detert J, Richter C, Kumke T, Leunikava I, Lendl U, Fricke D, Müller-Ladner U.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):842-851. Epub 2019 Mar 7.

PMID:
30873942
26.

Do musculoskeletal ultrasound and magnetic resonance imaging identify synovitis and tenosynovitis at the same joints and tendons? A comparative study in early inflammatory arthritis and clinically suspect arthralgia.

Ohrndorf S, Boer AC, Boeters DM, Ten Brinck RM, Burmester GR, Kortekaas MC, van der Helm-van Mil AHM.

Arthritis Res Ther. 2019 Feb 14;21(1):59. doi: 10.1186/s13075-019-1824-z.

27.

IgG4-related diseases: state of the art on clinical practice guidelines.

Iaccarino L, Talarico R, Scirè CA, Amoura Z, Burmester G, Doria A, Faiz K, Frank C, Hachulla E, Hie M, Launay D, Montecucco C, Monti S, Mouthon L, Tincani A, Toniati P, Van Hagen PM, Van Vollenhoven RF, Bombardieri S, Mueller-Ladner U, Schneider M, Smith V, Cutolo M, Mosca M, Alexander T.

RMD Open. 2019 Jan 19;4(Suppl 1):e000787. doi: 10.1136/rmdopen-2018-000787. eCollection 2018. Review.

28.

Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2019 May;39(5):945. doi: 10.1007/s00296-018-4232-9.

29.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Ann Rheum Dis. 2019 Jul;78(7):872-878. doi: 10.1136/annrheumdis-2018-214280. Epub 2019 Feb 2. Review.

PMID:
30712015
30.

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.

Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, Issa M, Salinas CA, Saifan C, Zhang X, Cardoso A, González-Gay MA, Takeuchi T.

Arthritis Rheumatol. 2019 Jul;71(7):1042-1055. doi: 10.1002/art.40841. Epub 2019 May 25.

31.

Systemic lupus erythematosus: state of the art on clinical practice guidelines.

Tamirou F, Arnaud L, Talarico R, Scirè CA, Alexander T, Amoura Z, Avcin T, Bortoluzzi A, Cervera R, Conti F, Cornet A, Devilliers H, Doria A, Frassi M, Fredi M, Govoni M, Houssiau F, Lladò A, Macieira C, Martin T, Massaro L, Moraes-Fontes MF, Pamfil C, Paolino S, Tani C, Tas SW, Tektonidou M, Tincani A, Van Vollenhoven RF, Bombardieri S, Burmester G, Eurico FJ, Galetti I, Hachulla E, Mueller-Ladner U, Schneider M, Smith V, Cutolo M, Mosca M, Costedoat-Chalumeau N.

RMD Open. 2018 Nov 27;4(2):e000793. doi: 10.1136/rmdopen-2018-000793. eCollection 2018. Review.

32.

[Higher prevalence of depressive and anxiety symptoms in early arthritis patients in comparison to the normal population].

Freier D, Englbrecht M, Höhne-Zimmer V, Detert J, Burmester GR.

Z Rheumatol. 2019 Nov;78(9):820-831. doi: 10.1007/s00393-018-0571-x. German.

PMID:
30511171
33.

Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?

Avci AB, Feist E, Burmester GR.

BioDrugs. 2018 Dec;32(6):531-546. doi: 10.1007/s40259-018-0320-3.

PMID:
30488231
34.

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.

Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH.

Rheumatol Int. 2019 Jan;39(1):131-140. doi: 10.1007/s00296-018-4180-4. Epub 2018 Nov 10.

35.

Antiphospholipid syndrome: state of the art on clinical practice guidelines.

Limper M, Scirè CA, Talarico R, Amoura Z, Avcin T, Basile M, Burmester G, Carli L, Cervera R, Costedoat-Chalumeau N, Doria A, Dörner T, Fonseca JE, Galetti I, Hachulla E, Launay D, Lourenco F, Macieira C, Meroni P, Montecucco CM, Moraes-Fontes MF, Mouthon L, Nalli C, Ramoni V, Tektonidou M, van Laar JM, Bombardieri S, Schneider M, Smith V, Vieira A, Cutolo M, Mosca M, Tincani A.

RMD Open. 2018 Oct 18;4(Suppl 1):e000785. doi: 10.1136/rmdopen-2018-000785. eCollection 2018.

36.

Systemic sclerosis: state of the art on clinical practice guidelines.

Smith V, Scirè CA, Talarico R, Airo P, Alexander T, Allanore Y, Bruni C, Codullo V, Dalm V, De Vries-Bouwstra J, Della Rossa A, Distler O, Galetti I, Launay D, Lepri G, Mathian A, Mouthon L, Ruaro B, Sulli A, Tincani A, Vandecasteele E, Vanhaecke A, Vanthuyne M, Van den Hoogen F, Van Vollenhoven R, Voskuyl AE, Zanatta E, Bombardieri S, Burmester G, Eurico FJ, Frank C, Hachulla E, Houssiau F, Mueller-Ladner U, Schneider M, van Laar JM, Vieira A, Cutolo M, Mosca M, Matucci-Cerinic M.

RMD Open. 2018 Oct 18;4(Suppl 1):e000782. doi: 10.1136/rmdopen-2018-000782. eCollection 2018.

37.

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2018 Dec;38(12):2225-2231. doi: 10.1007/s00296-018-4173-3. Epub 2018 Oct 20. Erratum in: Rheumatol Int. 2019 Feb 5;:.

38.

Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts.

Baganz L, Richter A, Albrecht K, Schneider M, Burmester GR, Zink A, Strangfeld A.

Semin Arthritis Rheum. 2019 Jun;48(6):976-982. doi: 10.1016/j.semarthrit.2018.09.003. Epub 2018 Sep 17.

39.

Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis.

Diekhoff T, Ulas ST, Poddubnyy D, Schneider U, Hermann S, Biesen R, Burmester GR, Hamm B, Hermann KG.

Ann Rheum Dis. 2019 Jan;78(1):31-35. doi: 10.1136/annrheumdis-2018-213904. Epub 2018 Sep 29.

40.

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.

Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR, Benichou O, Adams DH, Xu W, Nash P.

Arthritis Care Res (Hoboken). 2019 Mar;71(3):367-378. doi: 10.1002/acr.23738. Epub 2019 Feb 12.

41.

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.

Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z.

42.

CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells.

Gaber T, Schönbeck K, Hoff H, Tran CL, Strehl C, Lang A, Ohrndorf S, Pfeiffenberger M, Röhner E, Matziolis G, Burmester GR, Buttgereit F, Hoff P.

Int J Mol Sci. 2018 Aug 7;19(8). pii: E2312. doi: 10.3390/ijms19082312.

43.

Observational study and brief analysis of diagnostic criteria in relapsing polychondritis.

Rose T, Schneider U, Bertolo M, Klotsche J, Casteleyn V, Biesen R, Burmester GR, Hiepe F.

Rheumatol Int. 2018 Nov;38(11):2095-2101. doi: 10.1007/s00296-018-4121-2. Epub 2018 Aug 6.

PMID:
30084004
44.

Response to: 'Digital health: a new dimension in rheumatology patient care' by Kataria and Ravindran.

Burmester GR.

Ann Rheum Dis. 2019 Oct;78(10):e104. doi: 10.1136/annrheumdis-2018-214154. Epub 2018 Aug 2. No abstract available.

PMID:
30072487
45.

Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors.

Alexander T, Cheng Q, Klotsche J, Khodadadi L, Waka A, Biesen R, Hoyer BF, Burmester GR, Radbruch A, Hiepe F.

Eur J Immunol. 2018 Sep;48(9):1573-1579. doi: 10.1002/eji.201847492. Epub 2018 Jul 30.

46.

[S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs].

Fiehn C, Holle J, Iking-Konert C, Leipe J, Weseloh C, Frerix M, Alten R, Behrens F, Baerwald C, Braun J, Burkhardt H, Burmester G, Detert J, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Krause A, Kuipers J, Lorenz HM, Müller-Ladner U, Nothacker M, Nüsslein H, Rubbert-Roth A, Schneider M, Schulze-Koops H, Seitz S, Sitter H, Specker C, Tony HP, Wassenberg S, Wollenhaupt J, Krüger K.

Z Rheumatol. 2018 Aug;77(Suppl 2):35-53. doi: 10.1007/s00393-018-0481-y. Review. German.

PMID:
29968101
47.

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.

Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Kivitz AJ, Smolen JS, Burmester GR.

RMD Open. 2018 Jun 17;4(1):e000602. doi: 10.1136/rmdopen-2017-000602. eCollection 2018.

48.

[Tips and tricks in court-Practical experience from a medical viewpoint].

Burmester GR.

Z Rheumatol. 2018 Sep;77(7):587-592. doi: 10.1007/s00393-018-0490-x. Review. German.

PMID:
29947948
49.

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.

Arthritis Res Ther. 2018 Jun 19;20(1):129. doi: 10.1186/s13075-018-1614-z.

50.

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.

Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS.

Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.

PMID:
29908669

Supplemental Content

Loading ...
Support Center